z-logo
Premium
Mesotherapy for skin rejuvenation: assessment of the subepidermal low‐echogenic band by ultrasound evaluation with cross‐sectional B‐mode scanning
Author(s) -
Lacarrubba Francesco,
Tedeschi Aurora,
Nardone Beatrice,
Micali Giuseppe
Publication year - 2008
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2008.00234.x
Subject(s) - photoaging , medicine , echogenicity , ultrasound , dermatology , high frequency ultrasound , radiology
  Skin‐targeted ultrasound is a noninvasive technique that has been extensively used to evaluate age‐related dermal changes, and the presence of a subepidermal low‐echogenic band (SLEB) has been related to chronic UVR exposure in several studies. Since SLEB echogenicity is photoage‐related, the aim of this study was to evaluate, through ultrasound imaging, the effects on skin photoaging of mesotherapy, a treatment approach currently used in cosmetic dermatology for skin rejuvenation. Twenty women (mean age: 46.7 range 40–60 years) with physical signs of moderate photoaging on the dorsum of the hands were enrolled and treated with multiple microinjections of hyaluronic acid (HA) salts of biotechnological origin (1.000 Kd) every week for 4 weeks. In all subjects, ultrasound evaluation was performed at each visit and 1 week after the last treatment to evaluate SLEB echogenicity changes during treatment. At the end of study, a statistically significant ( p  < 0.001) increase of SLEB echogenicity (with a mean increase of pixel numbers equal to 31.3%) was observed in 15 of 19 subjects who completed the study. Our preliminary study suggests that mesotherapy with HA may be an effective treatment for skin photoaging, as confirmed by ultrasound. Follow‐up investigations on larger series of patients are necessary to further evaluate the safety, effectiveness, and duration of effect of this possible therapeutic approach to skin photoaging.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here